ClinicalTrials.gg
CompletedNCT01740362Updated Jan 7, 2013Results posted

Pharmacokinetics Of CP-690,550 In Patients With Impaired Renal Function

A Phase 1 interventional study of CP-690,550 and CP-690,550 in Renal Impairment, sponsored by Pfizer. Completed at 4 sites in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-01-07.

Sponsored by Pfizer · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 37 studies in Renal Insufficiency by Pfizer — 2 open to participants now, 3 under way, none of them phase 3. Renal Insufficiency · Pfizer.

Enrollment
21st of 36
24 · median 30
Started
2003
the only one that year
Phase 1
23 of 37
2 open now
Registered
17th of 37
by date

Among the 37 studies in Renal Insufficiency by Pfizer, this one is the 21st largest by enrollment of the 36 interventional ones that give a count, is the only one that started in 2003, is one of 23 in phase 1, and was the 17th registered.

Renal Insufficiency

1,413 studies on the registry are indexed under Renal Insufficiency; 146 are open to participants now.

Browse Renal Insufficiency studies →

Open to participants now

2 of the 37 studies in Renal Insufficiency by Pfizer are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 92 Renal Insufficiency studies recruiting now, 48 (52%) set no upper age limit and 19 (21%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies in Renal Insufficiency by Pfizer, or all of them as a file.
02

Study summary

A study to evaluate the pharmacokinetics of CP-690,550 in subjects with mild, moderate or severe renal impairment, who do not require hemodialysis, compared to healthy controls.

03

Conditions studied

  • Renal Impairment

Browse trials for

Keywords

  • CP-690
  • 550
  • pharmacokinetics
  • renal impairment
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects with normal renal function: Subjects must be healthy with estimated >80 mL/min
  • Subjects with renal impairment: Subjects should be in good general health commensurate with the population with chronic kidney disease

Exclusion criteria

Exclusion Criteria:

  • Kidney transplant patients
  • Subjects with any condition possibly affecting drug absorption
  • Subjects with with the exception of adequately treated basal cell carcinoma of the skin
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Other
    Healthy volunteers

    Healthy volunteers

    Drug: CP-690,550

  • Experimental
    Mild renal impairment

    patients with mild (\>50 and ≤80 mL/min) renal impairment

    Drug: CP-690,550

  • Experimental
    Moderate renal impairment

    patients with moderate (≥30 and ≤50 mL/min) renal impairment

    Drug: CP-690,550

  • Experimental
    severe renal impairment

    patients with severe (\<30 mL/min) renal impairment

    Drug: CP-690,550

Interventions

  • 10 mg (2 x 5 mg tablets), single dose

  • 10 mg (2 x 5 mg tablets), single dose

  • 10 mg (2 x 5 mg tablets), single dose

  • 10 mg (2 x 5 mg tablets), single dose

06

What researchers measure

Primary outcomes

  1. Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)]

    AUC (0 - ∞) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞).

    Time frame: 0 (Pre-dose), 0.5, 1, 1.5, 2, 4, 8, 10, 12, 16, 24, 48 hours post-dose

  2. Maximum Observed Plasma Concentration (Cmax)

    Time frame: 0 (Pre-dose), 0.5, 1, 1.5, 2, 4, 8, 10, 12, 16, 24, 48 hours post-dose

  3. Time to Reach Maximum Observed Plasma Concentration (Tmax)

    Time frame: 0 (Pre-dose), 0.5, 1, 1.5, 2, 4, 8, 10, 12, 16, 24, 48 hours post-dose

  4. Plasma Decay Half-Life (t1/2)

    Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.

    Time frame: 0 (Pre-dose), 0.5, 1, 1.5, 2, 4, 8, 10, 12, 16, 24, 48 hours post-dose

  5. Renal Clearance (CL R)

    Renal clearance is the volume of plasma from which the drug is completely removed by the kidney in a given amount of time.

    Time frame: 0 (Pre-dose) to 12 hours post-dose, 12 to 24 hours post-dose

07

Results

Posted Jan 7, 2013

Participant flow

Participant flow — Overall Study
MilestoneCP-690,550 (Normal Renal Function)CP-690,550 (Mild Renal Insufficiency)CP-690,550 (Moderate Renal Insufficiency)CP-690,550 (Severe Renal Insufficiency)
Started6666
Completed6666
Not completed0000

Outcome measures

PrimaryArea Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)]

AUC (0 - ∞) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞).

Time frame:
0 (Pre-dose), 0.5, 1, 1.5, 2, 4, 8, 10, 12, 16, 24, 48 hours post-dose
Reported as:
Mean · nanogram*hour/milliliter (ng*hr/mL)
Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)]
nanogram*hour/milliliter (ng*hr/mL)CP-690,550 (Normal Renal Function)CP-690,550 (Mild Renal Insufficiency)CP-690,550 (Moderate Renal Insufficiency)CP-690,550 (Severe Renal Insufficiency)
Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)]268 ± 71.5370 ± 109396 ± 154615 ± 214
Statistical analysis
  • CP-690,550 (Normal Renal Function) vs CP-690,550 (Mild Renal Insufficiency) · Ratio of adjusted geometric means: 137.26 · 90% CI 96.77 to 194.69
  • CP-690,550 (Normal Renal Function) vs CP-690,550 (Moderate Renal Insufficiency) · Ratio of adjusted geometric means: 142.59 · 90% CI 100.53 to 202.24
  • CP-690,550 (Normal Renal Function) vs CP-690,550 (Severe Renal Insufficiency) · Ratio of adjusted geometric means: 222.71 · 90% CI 157.02 to 315.89
PrimaryMaximum Observed Plasma Concentration (Cmax)
Time frame:
0 (Pre-dose), 0.5, 1, 1.5, 2, 4, 8, 10, 12, 16, 24, 48 hours post-dose
Reported as:
Mean · ng/mL
Maximum Observed Plasma Concentration (Cmax)
ng/mLCP-690,550 (Normal Renal Function)CP-690,550 (Mild Renal Insufficiency)CP-690,550 (Moderate Renal Insufficiency)CP-690,550 (Severe Renal Insufficiency)
Maximum Observed Plasma Concentration (Cmax)94.2 ± 25.387.3 ± 23.2104 ± 47.5111 ± 28.6
Statistical analysis
  • CP-690,550 (Normal Renal Function) vs CP-690,550 (Mild Renal Insufficiency) · Ratio of adjusted geometric mean: 93.15 · 90% CI 67.22 to 129.06
  • CP-690,550 (Normal Renal Function) vs CP-690,550 (Moderate Renal Insufficiency) · Ratio of adjusted geometric mean: 104.17 · 90% CI 75.18 to 144.34
  • CP-690,550 (Normal Renal Function) vs CP-690,550 (Severe Renal Insufficiency) · Ratio of adjusted geometric mean: 117.65 · 95% CI 84.91 to 163.02
PrimaryTime to Reach Maximum Observed Plasma Concentration (Tmax)
Time frame:
0 (Pre-dose), 0.5, 1, 1.5, 2, 4, 8, 10, 12, 16, 24, 48 hours post-dose
Reported as:
Median · hours
Time to Reach Maximum Observed Plasma Concentration (Tmax)
hoursCP-690,550 (Normal Renal Function)CP-690,550 (Mild Renal Insufficiency)CP-690,550 (Moderate Renal Insufficiency)CP-690,550 (Severe Renal Insufficiency)
Time to Reach Maximum Observed Plasma Concentration (Tmax)0.75 (0.50 to 1.50)1.00 (0.50 to 1.50)0.75 (0.50 to 2.00)0.75 (0.50 to 1.50)
PrimaryPlasma Decay Half-Life (t1/2)

Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.

Time frame:
0 (Pre-dose), 0.5, 1, 1.5, 2, 4, 8, 10, 12, 16, 24, 48 hours post-dose
Reported as:
Mean · hours
Plasma Decay Half-Life (t1/2)
hoursCP-690,550 (Normal Renal Function)CP-690,550 (Mild Renal Insufficiency)CP-690,550 (Moderate Renal Insufficiency)CP-690,550 (Severe Renal Insufficiency)
Plasma Decay Half-Life (t1/2)2.37 ± 0.3632.83 ± 0.8572.88 ± 0.6533.77 ± 0.480
PrimaryRenal Clearance (CL R)

Renal clearance is the volume of plasma from which the drug is completely removed by the kidney in a given amount of time.

Time frame:
0 (Pre-dose) to 12 hours post-dose, 12 to 24 hours post-dose
Reported as:
Mean · mL/min
Renal Clearance (CL R)
mL/minCP-690,550 (Normal Renal Function)CP-690,550 (Mild Renal Insufficiency)CP-690,550 (Moderate Renal Insufficiency)CP-690,550 (Severe Renal Insufficiency)
Renal Clearance (CL R)113 ± 16.284.7 ± 28.727.4 ± 15.919.9 ± 7.52

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
CP-690,550 (Normal Renal Function)—0/6 (0%)0/6 (0%)
CP-690,550 (Mild Renal Insufficiency)—0/6 (0%)0/6 (0%)
CP-690,550 (Moderate Renal Insufficiency)—0/6 (0%)3/6 (50%)
CP-690,550 (Severe Renal Insufficiency)—0/6 (0%)1/6 (16.7%)
Most frequent other events
Most frequent other events
EventCP-690,550 (Normal Renal Function)CP-690,550 (Mild Renal Insufficiency)CP-690,550 (Moderate Renal Insufficiency)CP-690,550 (Severe Renal Insufficiency)
Respiratory tract infectionRespiratory, thoracic and mediastinal disorders0/60/62/60/6
HypertensionCardiac disorders0/60/60/61/6
Tooth disorderGastrointestinal disorders0/60/61/60/6

Baseline characteristics

Age Continuous
Age Continuous(years)CP-690,550 (Normal Renal Function)CP-690,550 (Mild Renal Insufficiency)CP-690,550 (Moderate Renal Insufficiency)CP-690,550 (Severe Renal Insufficiency)Total
Mean50.8 ± 9.761.2 ± 2.853.5 ± 11.159.0 ± 14.656.1 ± 10.7
Sex: Female, Male
Sex: Female, Male(Participants)CP-690,550 (Normal Renal Function)CP-690,550 (Mild Renal Insufficiency)CP-690,550 (Moderate Renal Insufficiency)CP-690,550 (Severe Renal Insufficiency)Total
Female224311
Male442313
08

Study locations

4 sites
  • Pfizer Investigational Site
    Orlando, Florida 32806, United States
  • Pfizer Investigational Site
    New Orleans, Louisiana 70118, United States
  • Pfizer Investigational Site
    New Orleans, Louisiana 70119, United States
  • Pfizer Investigational Site
    Minneapolis, Minnesota 55404, United States
09

References and documents

Publications

  • Krishnaswami S, Chow V, Boy M, Wang C, Chan G. Pharmacokinetics of tofacitinib, a janus kinase inhibitor, in patients with impaired renal function and end-stage renal disease. J Clin Pharmacol. 2014 Jan;54(1):46-52. doi: 10.1002/jcph.178. Epub 2013 Sep 30. PubMed 24030917 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2003, a primary completion of Mar 2004 and a completion of Mar 2004. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2013, 8 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 16, 2012
First posted
Dec 4, 2012
Start
Oct 2003
Primary completionActual
Mar 2004
CompletionActual
Mar 2004
Results first posted
Jan 7, 2013
Last update
Jan 7, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 7, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01740362
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Dec 4, 2012
Start date
Oct 2003
Primary completion
Mar 2004
Completion
Mar 2004
Results posted
Jan 7, 2013
Last update
Jan 7, 2013

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tofacitinib

Start the discussion